TriangleNCT05191472 · OUTCOME
Proportion of Participants With Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months
What was measured
The Proportion of participants with reported ICANS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported
Analysis population: Data not collected
Groups in this outcome
Treatment (Pembrolizumab)
Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Pembrolizumab) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- The Proportion of participants with reported ICANS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported
- groups
- description
- Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Pembrolizumab)
- population Description
- Data not collected
- reporting Status
- POSTED
- time Frame
- Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months
- title
- Proportion of Participants With Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS)
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice